greeksoup/ stock research
Stock research / United States / Funds / Artia Global Partners LP

Artia Global Partners LP

CIK 1937964 · latest 13F filed 14 August 2026 · Read the filing on EDGAR

Artia Global Partners LP reported 47 US-listed holdings worth $526.0 million in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Abivax SA (13.1%), Insmed Inc. (11.9%) and Trevi Therapeutics Inc. (7.8%). Against the quarter before, it opened 7 positions, added to 10, trimmed 3 and sold out of 8.

Reported holdings$526.0M+18.6% on Q1 2026
Positions47-1 on Q1 2026
The largest ten66.5%of its reported holdings
Latest 13FQ2 2026filed 14 August 2026
Where the money is
OpenedAdded toHeldTrimmed
ABVX13.1%INSM11.9%TRVI7.8%BTSG6.9%RVMD6.6%ARGX5.2%ALKS4.5%TVTX3.7%AZN3.5%NAMS3.2%DNTH3.0%DGX2.6%IONS2.2%EYPT2.1%33 more23.6%

The 14 largest of its 47 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.

Reported holdings, quarter by quarter
Q3 2024: $353.6 million in 44 positions$354MQ3 24Q4 2024: $248.0 million in 33 positions$248MQ4 24Q1 2025: $341.0 million in 32 positions$341MQ1 25Q2 2025: $388.8 million in 33 positions$389MQ2 25Q3 2025: $568.3 million in 48 positions$568MQ3 25Q4 2025: $622.4 million in 50 positions$622MQ4 25Q1 2026: $443.5 million in 48 positions$444MQ1 26Q2 2026: $526.0 million in 47 positions$526MQ2 26

What the fund reported holding at each quarter's end; hover a bar for the number of positions

What its reported holdings returned

Held through each quarter, the holdings it reported returned +25.8% over the 7 quarters to 30 June 2026, against +30.2% for the S&P 500.

Its reported holdingsThe S&P 500
90105120135Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Its holdings +25.8%S&P 500 +30.2%

Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.

What it did on the quarter

Opened 7Added 10Held 27Trimmed 3Sold out 8
Opened: 7Added: 10Held: 27Trimmed: 3Sold out: 8

Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held

Opened 7

  1. Alkermes plc. ALKS$23.5 million
  2. Guardant Health Inc. GH$5.7 million
  3. Absci Corporation ABSI$5.4 million
  4. Ascendis Pharma A/s ASND$4.7 million
  5. Oruka Therapeutics Inc. ORKA$3.2 million
  6. Compass Therapeutics Inc. CMPX$839,208
  7. Spyre Therapeutics Inc. SYRE$355,120

Added to 10

  1. BrightSpring Health Services, Inc. BTSG+463,515 shares · +862%
  2. Travere Therapeutics Inc. TVTX+268,333 shares · +380%
  3. Revolution Medicines, Inc. RVMD+60,400 shares · +48%
  4. Quest Diagnostics Inc. DGX+24,305 shares · +60%
  5. Cytokinetics Inc. CYTK+54,400 shares · +334%
  6. Celcuity Inc. CELC+43,740 shares · +281%
  7. Trevi Therapeutics Inc. TRVI+197,250 shares · +10%
  8. Enliven Therapeutics Inc. ELVN+51,200 shares · +245%

and 2 more in the table below

Trimmed 3

  1. Abivax SA ABVX-84,300 shares · -14%
  2. Insmed Inc. INSM-39,660 shares · -6%
  3. Alumis Inc. ALMS-46,500 shares · -14%

Sold out of 8

  1. Eli Lilly & Co. LLY$35.2 million last quarter
  2. Terns Pharmaceuticals Inc. TERN$5.5 million last quarter
  3. Ascendis Pharma A/s ASND$4.1 million last quarter
  4. AbbVie Inc. ABBV$3.2 million last quarter
  5. Soleno Therapeutics Inc. SLNO$2.3 million last quarter
  6. Bridgebio Pharma Inc. BBIO$1.5 million last quarter
  7. Apogee Therapeutics Inc. APGE$495,425 last quarter
  8. Avalo Therapeutics Inc. AVTX$432,522 last quarter

What it holds

CompanySharesValueOf its bookChange in shares
Abivax SA ABVX516.4K$68.8 million13.08%-84.3K
Insmed Inc. INSM589.1K$62.8 million11.94%-39.7K
Trevi Therapeutics Inc. TRVI2.2M$41.2 million7.84%+197.2K
BrightSpring Health Services, Inc. BTSG517.3K$36.1 million6.86%+463.5K
Revolution Medicines, Inc. RVMD185.4K$34.7 million6.60%+60.4K
argenx SE ARGX29.7K$27.6 million5.25%no change
Alkermes plc. ALKS449.0K$23.5 million4.47%new
Travere Therapeutics Inc. TVTX339.0K$19.3 million3.66%+268.3K
AstraZeneca PLC AZN98.4K$18.7 million3.55%+3.0K
Newamsterdam Pharma Company NAMS503.9K$17.1 million3.25%no change
Dianthus Therapeutics Inc. DNTH163.0K$15.9 million3.02%no change
Quest Diagnostics Inc. DGX65.1K$13.8 million2.62%+24.3K
Ionis Pharmaceuticals Inc. IONS144.4K$11.4 million2.18%no change
Eyepoint Pharmaceuticals Inc. EYPT767.1K$11.0 million2.09%no change
Alumis Inc. ALMS278.5K$7.8 million1.49%-46.5K
Viking Therapeutics Inc. VKTX180.7K$7.1 million1.34%no change
Celcuity Inc. CELC59.3K$6.2 million1.18%+43.7K
Cytokinetics Inc. CYTK70.7K$6.0 million1.14%+54.4K
Merck & Co., Inc. MRK46.7K$6.0 million1.14%no change
Rapport Therapeutics Inc. RAPP138.5K$5.8 million1.10%no change
Johnson & Johnson JNJ22.6K$5.7 million1.09%no change
Guardant Health Inc. GH38.1K$5.7 million1.09%new
Absci Corporation ABSI464.4K$5.4 million1.02%new
Scholar Rock Holding Corporation SRRK96.3K$5.3 million1.01%no change
Sionna Therapeutics Inc SION119.7K$5.3 million1.00%no change
Ascendis Pharma A/s ASND17.7K$4.7 million0.90%new
Roivant Sciences Ltd. ROIV129.8K$4.6 million0.87%no change
Palisade Bio Inc. PALI2.0M$4.2 million0.79%no change
Edgewise Therapeutics Inc. EWTX98.8K$4.0 million0.76%+33.3K
Biogen Inc. BIIB18.4K$4.0 million0.76%no change
Xenon Pharmaceuticals Inc. XENE65.0K$3.9 million0.75%no change
Belite Bio Inc. BLTE25.0K$3.8 million0.73%no change
Mineralys Therapeutics Inc. MLYS137.8K$3.7 million0.71%no change
Prokidney Corp. PROK1.8M$3.7 million0.70%no change
Enliven Therapeutics Inc. ELVN72.1K$3.7 million0.70%+51.2K
Oruka Therapeutics Inc. ORKA33.4K$3.2 million0.60%new
Protagonist Therapeutics, Inc. PTGX23.0K$2.8 million0.53%+20
United Therapeutics Corp. UTHR5.0K$2.7 million0.52%no change
Bright Minds Biosciences Inc. DRUG38.4K$2.7 million0.51%no change
Kiniksa Pharmaceuticals Intl KNSA29.2K$1.9 million0.35%no change
Compass Therapeutics Inc. CMPX383.2K$839,2080.16%new
Praxis Precision Medicines I PRAX2.5K$836,9750.16%no change
Kodiak Sciences Inc. KOD17.0K$663,0600.13%no change
Tenax Therapeutics Inc. TENX42.1K$612,2640.12%no change
Nuvalent Inc. NUVL4.9K$605,1500.12%no change
Pepgen Inc. PEPG205.3K$369,5830.07%no change
Spyre Therapeutics Inc. SYRE4.0K$355,1200.07%new
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.
Read moreChange is shares against its 13F for the quarter before; the 8 it sold out of are in the box above.

Options it reported

CompanyOptionShares under the optionsValue of those shares
SPDR Ser Trust XBIPuts100.0K$15.8 million

1 option lines. A 13F lists calls and puts by the shares they cover and what those shares were worth at the quarter's end, not what the options cost; they are not counted in the holdings above.